Choosing First-Line Therapy in nAMD or DME
Experts expand on the discussion of first-line therapy choice, discussing how insurance mandates may alter treatment paths and the importance of catering to patient goals.
EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME
EP: 2.Choosing First-Line Therapy in nAMD or DME
EP: 3.When to Switch to More Efficacious Agents
EP: 4.Real-World Experiences With Faricimab
EP: 5.Real-World Experiences With Aflibercept 8mg
EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg
EP: 7.Perspectives on Retinal Fluid Management
EP: 8.Perspectives on Loading Dose Recommendations for New Therapies
EP: 9.Safety Considerations for New Therapies
EP: 10.The Impact of Biosimilars in Retinal Diseases
Summary
Experts delve into the importance of first-line therapy choice in retinal disease management. David Brown, MD acknowledges the influence of insurers on treatment options but emphasizes the clinical priority of reducing fluid and lesion size. Diana Do highlights her preference for FDA-approved, interval anti-VEGF inhibitors, specifically the second-generation therapies of aflibercept 8 mg or faricimab, due to their demonstrated efficacy and safety in phase 3 trials. She emphasizes the potential for these agents to control disease with fewer injections, addressing the visit burden on patients and caregivers. Seenu Hariprasad expands on the patient's perspective, emphasizing the significance of reduced injection frequency while maintaining vision, or even providing vision gains. Despite the many challenges in choosing the best first-line treatment for patients, the panel collectively values the extended durability and potential for improved drying with second-generation therapies, like aflibercept 8 mg and faricimab, aligning on patient-centered care.
This summary was AI-generated and edited for clarity.
